PARIS, April 30, 2015 /PRNewswire/ — Watch video interview and read transcript: http://www.eurobusinessmedia.com/ceo-direct/sanofi/interview-with-sanofi-cfo-jerome-contamine-q1-2015-results?utm_source=ceo-direct&utm_medium=wire Topics covered in the interview include: – Q1 2015 results – Guidance for 2015 – Recent launches – Diabetes – Genzyme – Animal Health and Consumer Healthcare – Vaccines – R&D pipeline – Emerging Markets About Sanofi Sanofi, a global healthcare leader, discovers, […]
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
DUBLIN, April 29, 2015 /PRNewswire/ — Perrigo Company plc (“Perrigo”) (NYSE: PRGO; TASE) today announced its rejection of the revised unsolicited offer from Mylan NV (“Mylan”) (NASDAQ: MYL) to acquire all of the outstanding shares of Perrigo for $75.00 per share in cash and 2.3 Mylan ordinary shares for each ordinary Perrigo share (the “Offer”). The […]
Celgene (CELG) Dealmaking Continues With Two Pacts Worth $110 Million With Northern Biologics, Agios (AGIO)
CAMBRDIGE, Mass. – Celgene Corporation (CELG) has struck two deals with other pharmaceutical companies with a combined value of $110 million to advance its oncology platform, continuing the cancer drugmaking company’s deal making trend to advance its oncology pipeline. Today Celgene announced it entered into an $80 million agreement with Agios Pharmaceuticals (AGIO) to develop […]
Pittsburgh, Penn.-based Mylan Pharmaceuticals, Inc. (MYL)’s has upped its previous $30 billion unsolicited bid for generic drugmaker Perrigo Company (PRGO) to $32.7 billion, a move Mylan said its advisors Goldman Sachs says is well in line with the “sufficient resources” the company has to tender such an offer. The new bid breaks down to $232.23 […]
New Business Pulse Focuses on CDC’s Efforts to Protect American Workers’ Heart Health ATLANTA, GA–(Marketwired – April 29, 2015) – Nearly 800,000 Americans die each year from heart disease, stroke and other cardiovascular diseases, accounting for one in every three deaths. Annually, about one in every six U.S. healthcare dollars is spent on cardiovascular disease. […]
POTTERS BAR, England, April 29, 2015 /PRNewswire/ — Mylan N.V. (NASDAQ: MYL) today announced that, further to its announcement issued pursuant to Rule 2.5 of the Irish Takeover Rules on April 24, 2015 (the “Rule 2.5 Announcement“), it has increased its offer to acquire the issued and to be issued shares of Perrigo (NYSE: PRGO; TASE). Under the terms of […]
(Reuters) – U.S. drugmaker Pfizer Inc (PFE.N) cut its full-year revenue and profit forecast, blaming a stronger dollar. However, the drugmaker reported a better-than-expected first-quarter profit, helped by demand for its vaccines and cancer drugs. Pfizer’s shares were roughly unchanged at $34.62 in premarket trade on Tuesday morning. The company, which got 60 percent of […]
(Reuters) – Investors betting that Bristol-Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales. Bristol shares fell as much as 2.7 percent and closed off 1 percent after reporting sales […]
(Reuters) – Merck & Co’s (MRK.N) shares jumped almost 5 percent after the U.S. drugmaker reported better-than-expected quarterly results and released favorable data late Monday about the safety of its Januvia diabetes drug. The second-largest U.S. drugmaker on Tuesday said it earned $953 million, or 33 cents per share, in the first quarter. That compared […]
(Reuters) – Bristol-Myers Squibb Co (BMY.N) reported better-than- expected quarterly results, helped by cost cuts and a higher estimate of royalties owed the company from sales of its Abilify schizophrenia treatment. The U.S. drugmaker, whose shares rose 2 percent in premarket trading, on Tuesday said it earned $1.19 billion, or 71 cents per share, in […]